384 results on '"Frost, Adaani E."'
Search Results
2. Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study
3. United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics
4. The Association of Pretransplant Pulmonary Hypertension With Patient and Graft Survival After Kidney Transplantation: A Retrospective Cohort Study
5. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial
6. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies
7. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
8. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score
9. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL
10. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry
11. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis
12. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
13. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
14. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
15. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry
16. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis
17. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
18. Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
19. Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension: A REVEAL Registry Analysis
20. Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension
21. Demographics and Outcomes of Patients Diagnosed With Pulmonary Hypertension With Pulmonary Capillary Wedge Pressures 16 to 18 mm Hg: Insights From the REVEAL Registry
22. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial
23. Application of the REVEAL risk score calculator 2.0 in the CHEST study
24. An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry
25. Delay in Recognition of Pulmonary Arterial Hypertension: Factors Identified From the REVEAL Registry
26. The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States: How REVEAL Differs From Historic and Non-US Contemporary Registries
27. The echocardiographic course of pretransplant pulmonary hypertension following kidney transplantation and associated outcomes
28. Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry
29. Application of the REVEAL risk score calculator 2.0 in the PATENT study
30. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension
31. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
32. Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
33. Optimization of Acute Kidney Injury (AKI) Time Definitions Using the Electronic Health Record: A First Step in Automating In-Hospital AKI Detection
34. Defining Vasoplegia Following Durable, Continuous Flow Left Ventricular Assist Device Implantation
35. Correlation of Chest Radiograph Pattern With Genotype, Age, and Gender in Adult Cystic Fibrosis: A Single-Center Study
36. United States Pulmonary Hypertension Scientific Registry
37. Transbronchial Biopsies: Clinical Perspective
38. Response
39. Outcomes of kidney transplantation using deceased donors with history of diabetes
40. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect
41. Lung Retransplantation After Posttransplantation Lymphoproliferative Disorder (PTLD): A Single-Center Experience and Review of Literature of PTLD in Lung Transplant Recipients
42. Defining Vasoplegia Following Durable, Continuous Flow Left Ventricular Assist Device Implantation.
43. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial
44. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
45. ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
46. Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Hypertension
47. Response
48. Scedosporium apiospermum Fungemia in a Lung Transplant Recipient*
49. Respiratory Control During Independent Lung Ventilation*
50. Respiratory and Limb Muscle Function in Lung Allograft Recipients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.